Contact
searchSearch
HMP Global
Login

News

News
Gilteritinib Following AlloHCT Shows No Improvement in Health-Related Quality of Life Among Patients With FLT3-ITD AML
10/31/2024
Gilteritinib maintenance therapy following allogeneic hematopoietic cell transplantation among patients with FLT3-ITD acute myeloid leukemia was not associated with any difference in health-related quality of life when compared with a...
Gilteritinib maintenance therapy following allogeneic hematopoietic cell transplantation among patients with FLT3-ITD acute myeloid leukemia was not associated with any difference in health-related quality of life when compared with a...
Gilteritinib maintenance therapy...
10/31/2024
Oncology
Jonathan Canaani, MD
Conference Coverage
Advances in Risk Stratification and Treatment for Patients With AML
10/24/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Jonathan Canaani, MD, discusses advancements in risk stratification and prognosis among patients with acute myeloid leukemia.
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Jonathan Canaani, MD, discusses advancements in risk stratification and prognosis among patients with acute myeloid leukemia.
At the 2024 Lymphoma, Leukemia &...
10/24/2024
Oncology
Justin Kaner, MD
Conference Coverage
Optimizing Treatment Methods Among Patients With Newly Diagnosed AML
10/17/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Justin Kaner, MD, discusses various treatment methods that optimize management of patients with newly diagnosed acute myeloid leukemia, including transplant evaluations and timeliness of test...
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Justin Kaner, MD, discusses various treatment methods that optimize management of patients with newly diagnosed acute myeloid leukemia, including transplant evaluations and timeliness of test...
At the 2024 Lymphoma, Leukemia &...
10/17/2024
Oncology
News
Treatment With 131L-Apamistamab Before AlloHCT Demonstrates Efficacy, Safety Among Older Patients With R/R AML
10/15/2024
According to phase 3 results from the SIERRA trial, anti-CD45 radioconjugate 131I-apamistamab was well-tolerated and showed a higher durable complete remission rate than standard care among older patients with relapsed/refractory acute...
According to phase 3 results from the SIERRA trial, anti-CD45 radioconjugate 131I-apamistamab was well-tolerated and showed a higher durable complete remission rate than standard care among older patients with relapsed/refractory acute...
According to phase 3 results...
10/15/2024
Oncology
News
Determining Optimal Daunorubicin Dosing and 7 + 3 Induction Cycles for Frontline AML Treatment
10/04/2024
High-dose daunorubicin once daily using standard 7 + 3 induction did not significantly improve response rates among patients with newly diagnosed acute myeloid leukemia and did not lead to higher remission rates or improved survival when...
High-dose daunorubicin once daily using standard 7 + 3 induction did not significantly improve response rates among patients with newly diagnosed acute myeloid leukemia and did not lead to higher remission rates or improved survival when...
High-dose daunorubicin once...
10/04/2024
Oncology
News
New Risk Stratification Model Provides Prognostic Data on Survival Post-AlloHCT for Older Patients With AML and High-Risk MDS
09/17/2024
The AML60+ classification system demonstrated efficacy in providing prognostic information for intensively treated patients 60 years and older with AML and high-risk MDS, and in identifying patients who would benefit from chemotherapy and...
The AML60+ classification system demonstrated efficacy in providing prognostic information for intensively treated patients 60 years and older with AML and high-risk MDS, and in identifying patients who would benefit from chemotherapy and...
The AML60+ classification system...
09/17/2024
Oncology
News
Poor Prognosis for Subset of Patients With AML With Monocytic Differentiation Treated With Frontline Venetoclax and Hypomethylating Agents
08/28/2024
Study data shows that a poor prognosis following treatment of frontline venetoclax and hypomethylating agents was demonstrated among a subset of patients with newly diagnosed acute myeloid leukemia with a monocytic immunophenotype.
Study data shows that a poor prognosis following treatment of frontline venetoclax and hypomethylating agents was demonstrated among a subset of patients with newly diagnosed acute myeloid leukemia with a monocytic immunophenotype.
Study data shows that a poor...
08/28/2024
Oncology
News
MRD Monitoring for Potential for Relapse Following Allogeneic Hematopoietic Cell Transplantation Among Patients With AML
08/28/2024
According to a study, a detection benefit was shown in next-generation sequencing monitoring of measurable residual disease as related to potential for relapse for patients with acute myeloid leukemia after alloHCT, which supports monthly...
According to a study, a detection benefit was shown in next-generation sequencing monitoring of measurable residual disease as related to potential for relapse for patients with acute myeloid leukemia after alloHCT, which supports monthly...
According to a study, a...
08/28/2024
Oncology
News
Complete Remission With Partial Hematological Recovery Shows Benefit as Palliative End Point for Nonmyelosuppressive Treatment of Patients With AML
08/14/2024
Complete remission with partial hematological recovery as an efficacy end point was found to correlate with clinical benefits associated with clinically meaningful palliative effects for the treatment of patients with acute myeloid leukemia...
Complete remission with partial hematological recovery as an efficacy end point was found to correlate with clinical benefits associated with clinically meaningful palliative effects for the treatment of patients with acute myeloid leukemia...
Complete remission with partial...
08/14/2024
Oncology
Curtis Lachowiez, MD
Videos
Exploring Triplet Therapy for Patients With AML Ineligible for Intensive Induction Chemotherapy
08/05/2024
Curtis Lachowiez, MD, participated in a debate at the 2024 Great Debates and Updates meeting in which he argued in favor of triplet therapy for patients with acute myeloid leukemia who are unable to receive intensive induction chemotherapy.
Curtis Lachowiez, MD, participated in a debate at the 2024 Great Debates and Updates meeting in which he argued in favor of triplet therapy for patients with acute myeloid leukemia who are unable to receive intensive induction chemotherapy.
Curtis Lachowiez, MD,...
08/05/2024
Oncology

Recent News

News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use